Nuvation Bio (NYSE: NUVB) is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
Location: United States, New York
Employees: 51-200
Total raised: $275M
Founded date: 2018
Investors 7
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | Omega Fund... | omegafunds... |
| - | Ally Bridg... | ally-bridg... |
| - | Biobrit | biobrit.co... |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Perceptive... | perceptive... |
| - | Altitude L... | altitudels... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 31.10.2019 | Series A | $275M | Omega Fund... |
Mentions in press and media 25
| Date | Title | Description |
| 02.08.2024 | Singapore to merge EDBI, SEEDS Capital to form SG Growth Capital | Singapore will merge two state-backed investment agencies, EDBI and SEEDS Capital, to form a new entity next year, according to an announcement on Friday. EDBI, the investment arm of Singapore’s Economic Development Board (EDB), and SEEDS C... |
| 02.06.2024 | Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting | SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 20.01.2022 | Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors | NEW YORK, Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that th... |
| 15.12.2021 | Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme | NEW YORK, Dec. 15, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that th... |
| 13.12.2021 | Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer | NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that th... |
| 08.12.2021 | Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer | NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the... |
| 11.11.2021 | Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update | NEW YORK, Nov. 10, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financia... |
| 10.11.2021 | Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update | NEW YORK, Nov. 10, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financia... |
| 12.08.2021 | Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update | NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financia... |
Show more